Literature DB >> 2582446

Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside.

P O Livingston1, G Ritter, P Srivastava, M Padavan, M J Calves, H F Oettgen, L J Old.   

Abstract

The ganglioside GM2 is a differentiation antigen expressed on the cell surface of human malignant melanomas and other cancers of neuroectodermal origin. We have previously reported that immunization with purified GM2 combined with Bacillus Calmette-Guérin as adjuvant and pretreatment with low-dose cyclophosphamide induced production of antibodies against GM2 in five of six patients. We have now extended our study and analyzed the induced antibodies against GM2 were not detected. After immunization, high-titer IgM antibodies were induced in 17 of 24 patients, and high-titer IgG antibodies in eight cases. Additional treatment of 12 patients with cimetidine, a histamine H2 receptor antagonist reported to have antisuppressor cell activity, had no effect on GM2 antibody titers. Antibodies against asialo-GM2 were present in all patients, and antibodies against GM1 were present in 33% of patients, before and after immunization. Antibodies induced by immunization were specific for GM2, though some reacted predominantly with N-acetylneuraminic acid GM2 (GM2), and some reacted with GM2 and N-glycolylneuraminic acid GM2(NeuGcGM2). The pattern of reactivity with GM2 is consistent with the response to T-cell-independent antigens: both IgM and IgG antibody responses against GM2 were short lived; peak titers seen after initial and secondary vaccinations were similar; and delayed-type hypersensitivity responses to skin test challenges with GM2 were not detected in any patients. However, the IgG response typed as predominantly IgG1 and IgG3, not IgG2 as might be expected for carbohydrate antigens (which are generally T-cell-independent antigens). Because IgG1 and IgG3 antibody responses are usually to T-cell-dependent antigens, the humoral immune response elicited by GM2 vaccination has both T-cell-dependent and T-cell-independent characteristics. These IgM and IgG responses against this neuroectodermal differentiation antigen expressed on melanoma cells have been induced without evidence of neurological or other toxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2582446

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

Review 1.  Immunogenicity of glycolipids.

Authors:  J Portoukalian
Journal:  Clin Rev Allergy Immunol       Date:  2000-08       Impact factor: 8.667

Review 2.  Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues.

Authors:  P O Livingston; G Ragupathi; C Musselli
Journal:  J Clin Immunol       Date:  2000-03       Impact factor: 8.317

3.  Induction of primary antigen-specific immune reponses in SCID-hu-PBL by coupled T-B epitopes.

Authors:  P Ifversen; C Mårtensson; L Danielsson; C Ingvar; R Carlsson; C A Borrebaeck
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

4.  Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody.

Authors:  P B Chapman; A N Houghton
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

5.  Enhancement of specific immunoglobulin production in SCID-hu-PBL mice after in vitro priming of human B cells with superantigen.

Authors:  C Mårtensson; P Ifversen; C A Borrebaeck; R Carlsson
Journal:  Immunology       Date:  1995-10       Impact factor: 7.397

Review 6.  Prospects for the therapeutic use of anticancer vaccines.

Authors:  R S Chamberlain
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

7.  Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.

Authors:  Z G Wang; L J Williams; X F Zhang; A Zatorski; V Kudryashov; G Ragupathi; M Spassova; W Bornmann; S F Slovin; H I Scher; P O Livingston; K O Lloyd; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

8.  Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions.

Authors:  Gianni Gerlini; Adrian Tun-Kyi; Christa Dudli; Günter Burg; Nicola Pimpinelli; Frank O Nestle
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.

Authors:  K Kitamura; P O Livingston; S R Fortunato; E Stockert; F Helling; G Ritter; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

Authors:  S F Slovin; G Ragupathi; S Adluri; G Ungers; K Terry; S Kim; M Spassova; W G Bornmann; M Fazzari; L Dantis; K Olkiewicz; K O Lloyd; P O Livingston; S J Danishefsky; H I Scher
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.